CORC

在结果中检索

CORC

浏览/检索结果: 共11条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial 期刊论文
ONCOTARGETS AND THERAPY, 2018, 卷号: 11
作者:  Wu, Yi-Long;  Xu, Chong-Rui;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：16/0  |  提交时间：2019/12/04
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 卷号: 11, 期号: 1
作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/04
Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11
作者:  Hirsh, V.;  Tan, E.;  Wu, Y.;  Sequist, L.;  Zhou, C.
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/04
Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC 期刊论文
Journal of Thoracic Oncology, 2017, 卷号: 12
作者:  null
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials 期刊论文
ANNALS OF ONCOLOGY, 2016, 卷号: 27, 期号: 11
作者:  Zhou, C.;  Yang, J. C. -H.;  Sequist, L. V.;  Schuler, M.;  Geater, S. L.
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04
Symptom and Quality of Life Improvement in LUX-Lung 6 An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2015, 卷号: 10, 期号: 6
作者:  Geater, Sarayut L.;  Xu, Chong-Rui;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Jifeng
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/04
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials 期刊论文
LANCET ONCOLOGY, 2015, 卷号: 16, 期号: 2
作者:  Yang, James Chih-Hsin;  Wu, Yi-Long;  Schuler, Martin;  Sebastian, Martin;  Popat, Sanjay
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial 期刊论文
LANCET ONCOLOGY, 2014, 卷号: 15, 期号: 2
作者:  Wu, Yi-Long;  Zhou, Caicun;  Hu, Cheng-Ping
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/04
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2013, 卷号: 31, 期号: 15
作者:  Wu, Yi Long;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Ji Feng;  Lu, Shun
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung 期刊论文
EUROPEAN RESPIRATORY JOURNAL, 2013, 卷号: 42
作者:  Wu, Yi-Long;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/04

©版权所有 ©2017 CSpace - Powered by CSpace